3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
3
Triple Negative Breast Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Mesothelioma, Malignant
1
Mesothelioma
1
Lung Neoplasms
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Interventions
pembrolizumab
63
Nivolumab
44
atezolizumab
14
Docetaxel
10
Cyclophosphamide
10
Paclitaxel
9
Magnetic Resonance Spectroscopy
9
Ipilimumab
9
avelumab
8
Specimen Handling
8
durvalumab
7
Radiosurgery
7
Cetuximab
7
spartalizumab
6
Radiotherapy
6
Immune Checkpoint Inhibitors
6
Interleukin-2
5
Carboplatin
5
fludarabine
4
cabozantinib
4
Trastuzumab
4
Sunitinib
4
Psychiatric Rehabilitation
4
Pemetrexed
4
Oxaliplatin
4
Fluorodeoxyglucose F18
4
Everolimus
4
Cisplatin
4
Capecitabine
4
Bevacizumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Renal Cell
×
Blood Component Removal
×
Thoracic
×
Clear all
NCT04981119
2026-06-02
BASECAMP-1
A2 Biotherapeutics Inc.
Recruiting
200 enrolled